ALK Market Share Analysis for May 2026

ALK-Abelló A/S, also commonly known as ALK, is a Denmark-based pharmaceutical company which specializes in the development and manufacturing of allergy immunotherapy products for the prevention and treatment of allergy.

Health > Biotechnology and Pharmaceuticals

Domainalk.net

Year Founded1923

Employees1001 - 5000

Annual Revenue$500M - $1B

ALK

ALK (including company regionals)

alk.net

See more website traffic and engagement information

ALK Revenue up to May 2026 is 500M - 1B

revenue generated by ALK top domains

ALK top domains revenue over 3 years

Revenue for ALK top domains

alk.net500M - 1B

See more with Sales Intelligence

Total visits to ALK's top domains

Understand ALK market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

alk.net82.3K

See more with Sales Intelligence

Avg. visit duration in ALK's top domains

Analyze ALK engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

alk.net00:00:44

See more with Sales Intelligence

Avg. pageviews on ALK's top domains

See how ALK keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

alk.net1.93

See more with Sales Intelligence

ALK top competitors by domain

Top similar sites in May 2026, ranked by their affinity

stallergenesgreer.comCompany NameStallergenes GreerEmployees1001 - 5000HQUnited Kingdom, LondonAnnual revenue$200M - $500MTotal visits19.7KHealth > Biotechnology and Pharmaceuticals

Top technologies used by ALK

These are the website technologies, by industry, used by ALK top domains

Advertising (6)

DoubleClick

Social (4)

Instagram

Widget (4)

reCAPTCHA

Conversion & Analytics (3)

Google Analytics

More Technologies

8

See all

News & Signals from ALK

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsHenriette Mersebach leaves ALK company. as executive vice president, research and development.Danish allergy immunotherapy specialist ALK Abello(ALKB: DC) has announced that Henriette Mersebach will step down imminently as executive vice president, research and development, and as a member of the board.

NewsALK company. invests into Allegriatx $5.1M in Seed 1.ALLEGRIA Therapeutics, a biotech company redefining the treatment landscape of therapeutics for mast cell-mediated diseases, has secured USD 5.1 million in its seed extension financing led by ALK Abelló.

NewsALK company. launched EURneffy in Germany on Jun 1st '25.Its partner ALK-Abelló has launched EURneffy in Germany in June 2025 with plans to launch in the U.K. later this year.